ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

Hydridoma Cell Lines Available

March 5, 1982

CMS, FDA Developing Process For Concurrent Therapy ApprovalsAACI To Honor Mary-Claire King, Sen. Sherrod Brown

October 1, 2010

Working Group: Restructure NCI, Improve Review Process, Encourage Independence

July 14, 1995

Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy

July 26, 2013

Another HHS Recommendation: Screen 50 And Older For Colorectal Cancer;

March 15, 2002

NCI Supercomputer To Be Available To Extramural Scientists

June 8, 1984